Zanidatamab has also been tested against HER2-high (IHC 3+ or 2+, upon testing with in situ hybridization, ISH) breast (17 patients), gastric/esophageal (11 patients), or other (5 patients) cancers with progressive disease after SoC. The gene discussed is ERBB2; the disease is cancer.